Literature DB >> 25550563

Urological procedures in patients with peritoneal carcinomatosis of colorectal cancer treated with HIPEC: morbidity and survival analysis.

Hidde J Braam1, Thijs R van Oudheusden2, Ignace H J T de Hingh2, Simon W Nienhuijs2, Djamila Boerma3, Marinus J Wiezer3, Bert van Ramshorst3.   

Abstract

AIM: To investigate whether cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) is a feasible and effective option for patients with urological involvement of peritoneal carcinomatosis from colorectal cancer (CRC-PC). PATIENTS AND METHODS: The characteristics of patients with CRC-PC treated with CRS+HIPEC, with or without a urological procedure, between April 2005 and June 2013 in two tertiary Centres were analyzed.
RESULTS: Thirty-eight patients (14%) out of 267 CRC-PC patients treated with CRS+HIPEC had a urological procedure during cytoreduction. The median survival was not significantly different between patients with or without a urological procedure (26.9 versus 32.1 months, p=0.29). Severe complications occurred more in patients with a urological procedure (47% versus 20%, p<0.001). In patients with a urological procedure, the most frequent complications were gastrointestinal leakage (n=9) and intra-abdominal abscess formation (n=5).
CONCLUSION: Urological resections as a part of CRS+HIPEC in patients with peritoneal carcinomatosis of colorectal origin are feasible and effective. Severe complications are prevalent in these patients but survival is comparable to patients without involvement of the urinary system. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Colorectal neoplasms; hyperthermia; intraperitoneal chemotherapy; peritoneal neoplasms; postoperative complications; prognosis; urinary tract

Mesh:

Substances:

Year:  2015        PMID: 25550563

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

Review 2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.

Authors:  Andrew D Newton; Edmund K Bartlett; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

3.  The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Grace Hwei Ching Tan; Nicholas B Shannon; Claramae Shulyn Chia; Lui Shiong Lee; Khee Chee Soo; Melissa Ching Ching Teo
Journal:  Asian J Urol       Date:  2017-10-04

4.  Clinical features and surgical outcomes of major urological interventions during cytoreductive surgery and hyperthermic intraperitoneal chemotheraphy.

Authors:  Özgül Düzgün; Murat Kalın; Resul Sobay; Ömer Faruk Özkan
Journal:  Ther Adv Urol       Date:  2020-12-10

5.  Risk factors and clinical outcomes in patients undergoing cytoreductive surgery with concomitant ureteric reimplantation.

Authors:  Anais Alonso; Shoma Barat; Helen Kennedy; Meredith Potter; Nayef Alzahrani; David Morris
Journal:  Pleura Peritoneum       Date:  2021-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.